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ABSTRACT 
Objective: A new precise, accurate, sensitive and robust RP-HPLC method was developed for third generation cephalosporin and β lactamase 
inhibitor i.e. cefoperazone and tazobactam in marketed preparation.  
Methods: The Chromatographic separation was achieved on Thermo BDS Hypersil C18 column (250 × 4.6 mm i.d.5 µm) at ambient temperature. A 
Binary mobile phase consisting of 0.02 mM potassium dihydrogen phosphate buffer, pH 4.0 and Methanol (80:20, v/v) was delivered through a 
column at a flow rate of 1 ml/min. Measurement was performed at a desired wavelength of 250 nm.  
Result: The method was linear over the concentration range of 20-60 µg/mL (r2 = 0.9987) for cefoperazone (CEFO) and 2.5-7.5 µg/mL (r2 = 0.9998) 
for tazobactam (TAZO). The percentage content for cefoperazone 97.64±1.0 and of tazobactam was 97.13±0.96 in the marketed formulation. The 
low value of % Relative Standard Deviation (%RSD) was 0.78 and 0.43 for CEFO and TAZO, respectively, indicates the reproducibility of this 
method. Tailing Factors for CEFO and TAZO were less than 2. A LOD and LOQ low value suggests the sensitiveness of method. The method was 
validated for linearity, precision, accuracy, and robustness as per ICH guideline. 
Conclusion: It can be concluded from the results that the proposed RP-HPLC method was found to be simple, accurate, robust and precise for the 
analysis of cefoperazone and tazobactam in bulk and sterile dried injection dosage forms. This method was validated as per ICH guidelines. Thus, it 
can be used for routine quality control studies for assay of cefoperazone and tazobactam simultaneously. 
Keywords: Cefoperazone, Tazobactam, Simultaneous estimation, Validation, RP- HPLC. 
 
INTRODUCTION 
Infectious diseases have always been created the threat to human 
being and animals[1]. Therefore, the treatment is necessary using 
suitable antimicrobial agents. Although various antibiotics have 
been developed but cephalosporin group of antibiotics are widely 
used[2]. Cefoperazone is a third generation cephalosporin antibiotic 
indicated for the treatment of patients infected with susceptible 
strains of microorganisms like respiratory tract, skin and soft tissue, 
bone and joint infections, septicemia, meningitis[3]. Cefoperazone 
(CEFO) is chemically [6R-[6alpha,7beta(R)]]-7-[[[[(4-Ethyl-2,3-
dioxo-1-piperazinyl)carbonyl]amino](4-hydroxy phenyl) 
acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-
thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid. The chemical 
structure of CEFO is presented in figure 1. It is official drug in Indian 
Pharmacopoeia [4], British Pharmacopoeia [5].  
Tazobactam (TAZO) is a compound that inhibits the action of 
bacterial ß-lactamase. TAZO is semi-synthetic parenteral penicillin 
with a broad spectrum of antibacterial activity [6-7]. Tazobactam 
(TAZO) chemically known as (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-
1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylic acid 4,4-dioxide (Figure 2). TAZO is not official drug in 
any Pharmacopoeia.  
The combination of CEFO and TAZO is more effective for the 
treatment of moderate to severe infections than single drug therapy 
alone. CEFO and TAZO combination are used for the treatment of 
urinary tract infections and skin infections. A literature survey 
revealed that a liquid chromatography method has been reported 
for determination of CEFO in formulation [8]. CEFO in combination 
with other drugs also have been estimated by various liquid 
chromatography methods [9-11]. TAZO was also successfully 
determined by HPLC, HPTLC [12, 13]. Till date no HPLC method is 
available for simultaneous estimation of CEFO and TAZO in 
combined dosage form. Therefore present work involves the 
development of a simple RP-HPLC method for simultaneous 
estimation of CEFO and TAZO in bulk as well as in pharmaceutical 
formulation. 
 
Fig. 1: Chemical structure of Cefoperazone 
 
 
Fig. 2: Chemical structure of Tazobactam 
 
MATERIALS AND METHODS  
The reference standard (RS) of CEFO and TAZO were obtained from 
Molecule Laboratory Pvt. Ltd, Ahmedabad, India. The fixed dose 
combination of CEFO and TAZO (Lupitam) was purchased from the 
local pharmacy. Each unit of Lupitam contains 1000 mg of 
Cefoperazone and 125 mg of Tazobactam. The Methanol (HPLC 
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grade) and potassium dihydrogen phosphate ( of AR grade) were 
obtained from Merck, Mumbai, India.  
Instrumentation and Chromatographic Conditions: 
Chromatographic separation was performed using chromatography 
(LC2010CHT, Shimadzu, Japan) system equipped with the Agilent 
SPD-20AT prominence diode array detector. Spin Chrome software 
was employed for data collecting and processing Chromatographic 
separation was performed on BDS Hypersil C-18 stainless steel 
column with dimensions of 250×4.6 mm, 5 µm particle size.  
A binary mobile phase consisting 0.02M potassium dihydrogen 
phosphate buffer, pH 4.0 and Methanol (80:20 v/v) was delivered 
through a column at a flow rate of 1 mL/min. The phosphate buffer, 
pH 4.0 and Methanol was filtered separately through a 0.45 µm 
membrane filter paper. The mobile phase was degassed before use. 
HPLC analysis[14,15] was performed at ambient temperature with 
detection at 250 nm. The injection volume was 20 µL.  
Preparation of standard stock solution  
Standard stock solution of CEFO (400µg/mL): An accurately 
weighed quantity of powder equivalent to 40.0 mg of CEFO was 
transferred to 100 mL volumetric flask. The drug was dissolved and 
diluted up to the mark with methanol.  
Standard stock solution of TAZO (50µg/mL): An accurately 
weighed quantity of powder equivalent to 5.0 mg of TAZO was 
transferred to 100 mL volumetric flask. The drug was dissolved and 
diluted up to the mark with methanol.  
Assay of marketed formulation: 
To determine the content, 10 vial units (Lupitam) were individually 
weighed and average weight was recorded. Dry powder from all 
vials was mixed together to make a pooled sample. A quantity of vial 
powder (≡ 40.0 mg of CEFO and 5.0 mg of TAZO) was weighed and 
transferred into 100 mL of volumetric flask.  
The mixture was dissolved in methanol, sonicated for 10 min and 
diluted to the up to mark with methanol to obtain a concentration of 
400 µg/mL of CEFO and 50 µg/mL of TAZO. The solution was 
filtered using Whatmann filter paper No. 41. This solution was 
further diluted with mobile phase to obtain final concentration of 
CEFO (40 µg/ml) and TAZO (5µg/ml). The final sample solution was 
filtered (Whatmann filter paper No. 41) and injected. Run time of 
analysis was kept 15 min and detection is carried out at 250 nm. All 
the determinations were carried out in triplicate.  
METHOD VALIDATION 
Validation of an analytical procedure is the process by which it is 
established by laboratory studies that the performance 
characteristics of the procedure meet the requirements for the 
intended analytical application. The developed chromatographic 
method was validated for system suitability, linearity and range, 
accuracy, precision, and robustness, as per ICH guidelines [16]. 
System suitability test 
The system suitability test was performed by five replicate analyses 
of working standard solution. Results of %RSD, retention time, 
theoretical plates and tailing factor (peak symmetry) are presented 
in Table 1. 
Analysis of marketed formulation 
Results of assay were in good agreement with the label claim. The 
drug content in the unit was found to be 97.64±1.00 % and 
97.13±0.963% for Cefoperazone and Tazobactam, respectively, are 
shown in Table 2. 
Linearity and range 
Working solutions were injected under the operating 
chromatographic conditions and peak areas for each drug were 
calculated at 250 nm. The calibration curve was plotted between 
areas against corresponding concentrations of each drug. Linear 
regression data for calibration curves were shown in Table 3. The 
range of solution has been decided according to correlation 
coefficient of regression equation. 
Accuracy (% recovery) 
The accuracy of the method was determined by calculating % 
recovery of each drug by standard addition method. Percent 
recovery of CEFO and TAZO was determined at three different level 
80%, 100% and 120% of the target concentration in triplicate, the 
results obtained were compared with expected results and 
statistically validated, are shown in Table 4. 
Precision 
Inter-day and Intraday precision were carried out in following 
concentration range 20, 40, 60μg/ml of CEFO and 2.5, 5, 7.5μg/ml of 
TAZO, respectively. At different time intervals in the same day and at 
the same time on different days. The variation in the results was 
analysed and statistically validated. The % relative standard 
deviation (%RSD) values for inter-day and intra-day precision for 
CEFO and TAZO are shown in Table 5. 
Robustness 
Robustness evaluation showed the reliability of analysis respect to 
deliberate variations in method parameters. The method was 
studied by changing flow rate (±0.2 ml/min), change in pH (±0.2), 
and change in mobile phase (±2%v/v) during analysis. Sample 
solution of 100% concentration is prepared and injected in triplicate 
for every condition and % Assay was calculated for each condition 
are shown in Table 6. 
LOD and LOQ 
The standard deviation of the Y-intercept and average slope of the 









LOD - Limit of detection, 
LOQ – Limit of quantitation  
Where, S is average value of slopes of calibration plots and SD is 
calculated using values of y intercepts of regression equations are 
shown in Table 7. 
RESULTS AND DISCUSSION 
Initially various mobile phases were tried in attempt to obtain the 
better separation and good resolution between CEFO and TAZO 
combined dosage form. Finally potassium dihydrogen phosphate 
(0.02M KH2PO4) Buffer: Methanol (80:20) at pH 4.0) was found to be 
an appropriate mobile phase allowing good separation of both the 
compounds using, Hypersil BDS C18 column at 40±5°C at 1 mL/min. 
flow rate. As the CEFO and TAZO exhibit significant absorbance at 
wavelength 250 nm, therefore it was selected as detection 
wavelength for simultaneous estimation of CEFO and TAZO in 
marketed formulation. These optimized conditions had acceptable 
system suitability parameters indicate good resolution for both the 
peaks (Table 1). The value of % Relative Standard Deviation (%RSD) 
was 0.78 and 0.43 for CEFO and TAZO, respectively, indicates 
reproducibility of the method. The Number of theoretical plates for 
CEFO and TAZO were 3523 and 4253, respectively, in acceptance 
limit. Tailing Factors for CEFO and TAZO were 1.54 and 1.56, 
respectively, not more than 2. LOD and LOQ for CEFO was 5.22, 
16.02 that for TAZO was 0.4245, 14.15, respectively (Table 7) and 
these values were acceptable and therefore the optimized conditions 
were used for further analysis. The retention time for CEFO and 
TAZO were 3.86 and 7.57 min., respectively. The values of 
correlation coefficient for CEFO and TAZO (Table 3) demonstrated 
the good relationship between peak area and concentration. 
Therefore, the developed method was linear in concentration range 
of 20-60 µg/mL for CEFO and 2.5 -7.5µg/mL for TAZO. The 
percentage assay of CEFO and TAZO in sterile dried powder samples 
were 97.64% and 97.13%, respectively (Table 2). Percent recovery 
was 99.51±0.70% for CEFO and 98.42±0.51% for TAZO 
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demonstrated accuracy. The high recovery obtained indicates that 
the proposed method is highly accurate. The low value of % RSD in 
intra-day and inter-day precision (Table 5) indicated reproducibility 
of this method.  
Finally, deliberate variations were made to check the significant 
variations in experimental conditions (Table 6) suggested 
robustness of developed method. 
 
 
Fig. 3: Standard Solution of CEFO and TAZO 
 
 
Fig. 4: Sample solution of CEFO and TAZO 
 
Table 1: Results of system suitability test 
Parameter Cefoperazone Tazobactam 
SD* 2490.83 2071.57 
%RSD* 0.783 0.435 
RT(min) 3.86 7.57 
Theoretical Plate 3523 4253 
Tailing Factor 1.54 1.56 
 *n=5 
Table 2: Results of Assay of Marketed formulation 
Parameters Cefoperazone Tazobactam 
Label Claim (mg) 1000 125 
Actual content found (mg) 974.68 122.73 
% Avg Assay(n=3) 97.64 97.13 
 
 
Fig. 5: Calibration curve of Cefoperazone 
 
 
Fig. 6: Calibration curve of Tazobactam 
 
Table 3: Linear regression data for calibration curves of 
Cefoperazone and Tazobactam 
Parameters Cefoperazone Tazobactam 
Linearity range (µg/ml) 20 – 60 2.5 –7.5 
Coefficient of correlation 0.9987 0.9998 
Slope  1574.00 1464.00 
Intercept  1449.00 1440.00 
 
 
Table 4: Accuracy data of CEFO and TAZO 




Mean % Recovery ± SD* % RSD* 
 
CEFO 
80% (16 µg/ml) 15.90 99.84% ± 0.5575 0.558 
100% (20 µg/ml) 19.90 99.51% ± 0.7084 0.711 
150% (24 µg/ml) 23.87 99.49% ± 0.1756 0.176 
 
TAZO 
80% (2 µg/ml) 1.96 99.17% ± 0.8605 0.867 
100% (2.5 µg/ml) 2.48 98.92% ± 0.5112 0.516 
120% (3.5 µg/ml) 2.95 98.94% ± 0.4056 0.409 
*n=3 
 
Table 5: Precision data of Cefoperazone and Tazobactam 
Parameter Cefoperazone Tazobactam 
Inter-day(%RSD)* 0.4606 0.6179 
Intra-day(%RSD)* 0.7839 0.4352 
(*n=6) 
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Table 6: Robustness studies of CEFO and TAZO 
Change in flow rate(1 ml/min) Flow rate(ml/min) Average* Std Dev %RSD 
Cefoperazone 1.2 ml/min 6011.004 69.80938 1.16136 
0.8 ml/min 6385.375 38.39933 0.60136 
Tazobactam 1.2 ml/min 5707.367 62.59649 1.09676 
0.8 ml/min 6066.191 63.03829 1.03917 
Change in mobile phase composition Buffer:Methanol(80:20)v/v Mobile phase(80:20)v/v Average* Std Dev %RSD 
Cefoperazone (78:22)v/v 6003.18 68.59503 1.142645 
(82:18)v/v 6307.907 58.89389 0.933652 
Tazobactam (78:22)v/v 5703.431 57.92355 1.015591 
(82:18)v/v 5998.32 52.38804 0.873379 
Change in pH(4.0) ±0.2 Change in pH Average* Std Dev %RSD 
Cefoperazone 4.2 5890.12 64.815 65.997 
3.8 6322.73 1.1004 1.0438 
Tazobactam 4.2 5598.82 54.336 50.325 
3.8 6013.94 0.9704 0.8368 
 *n=3 
 
Table 7: LOD and LOQ 
Parameter Cefoperazone Tazobactam 
LOD 5.22 0.4245 
LOQ 16.02 14.15 
 
CONCLUSION 
The present work represents the first report that deals with 
simultaneous analysis of cefoperazone and tazobactam in bulk and 
sterile dried injection dosage forms using RP-HPLC. It can be 
concluded from the results that the proposed method is simple, 
accurate, robust and precise. This method was validated as per ICH 
guidelines. Thus, it can be used for routine quality control studies for 
assay of cefoperazone and tazobactam. 
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